Valuation of neutrophil to lymphocyte ratio in peripheral blood as a prognostic factor for patients with triple negative breast cancer

doi:10.3760/cma.j.issn.1673422X.2017.11.005

Abstract

Abstract: ObjectiveTo analyze the clinical features of patients with triplenegative breast cancer (TNBC) and prognostic factors, and to analyze the correlation between neutrophiltolymphocyte ratio (NLR) in peripheral blood before operation and the prognosis of TNBC patients and investigate the value of NLR as a prognostic index for patients with TNBC. MethodsThe clinical data of 87 patients with TNBC treated in People′s Hospital of Jiangyin of Jiangsu Province from January 2008 to January 2013 were analyzed retrospectively. The patients were divided into low NLR group (NLR≤4.39, n=58) and high NLR group (NLR＞4.39, n=29) according to the NLR in peripheral blood before operation. The correlations between NLR and clinicpathological features were analyzed. KaplanMeier method was used to estimate the survival. The univariate analysis was done and Cox proportional hazards regression model was used for multivariate analysis to explore the effect of the NLR in peripheral blood before operation on survival of TNBC patients. ResultsThe high NLR value was related with the clinical stage (χ2=8.628, P=0.005) and lymph node metastasis (χ2=4.911, P=0.027). However, NLR was not correlated with age (χ2=0.575, P=0.448), pathological types (χ2=0.687，P=0.709), tumor size (χ2=3.523, P=0.172), smoking (χ2=0.536， P=0.474), drinking (χ2=0.043, P=0.837) or inheritance (χ2=0.315, P=0.585). Univariate analysis showed that lymph node metastasis (HR=2.02, P=0.021), clinical stage (HR=2.69, P=0.007) and NLR value (HR=2.26, P=0.014) were related to the overall survival of patients with TNBC. Cox multivariate analysis showed that clinical stage (HR=4.10, P=0.033) and NLR value (HR=3.44, P=0.016) were independent predictors of prognosis in patients with TNBC. ConclusionIn TNBC, the NLR level is related to clinical tumor stage and lymph node metastasis significantly. Furthermore, the higher NLR value is a novel independent prognostic risk factor, which has important implications on prognosis of patients with TNBC.

Key words: Breast neoplasms, Lymphocytes, Prognosis, Retrospective studies

潘宇凯. Valuation of neutrophil to lymphocyte ratio in peripheral blood as a prognostic factor for patients with triple negative breast cancer[J]. Journal of International Oncology, 2017, 44(11): 824-827.

References

［1］ O′Toole SA, Beith JM, Millar EK, et al. Therapeutic targets in triple negative breast cancer［J］. J Clin Pathol, 2013, 66(6): 530-542. DOI: 10.1136/jclinpath-2012-201361. ［2］ de Ruijter TC, Veeck J, de Hoon JP, et al. Characteristics of triplenegative breast cancer［J］. J Cancer Res Clin Oncol, 2011, 137(2): 183192. DOI: 10.1007/s00432-010-0957x. ［3］ Verma S, Provencher L, Dent R. Emerging trends in the treatment of triplenegative breast cancer in Canada: a survey［J］. Curr Oncol, 2011, 18(4): 180-190. ［4］ Brewster AM, ChavezMacGregor M, Brown P. Epidemiology, biology, and treatment of triplenegative breast cancer in women of African ancestry［J］. Lancet Oncol, 2014, 15(13): e625-e634. DOI: 10.1016/S1470-2045(14)70364X. ［5］ Zhang G, Xie W, Liu Z, et al. Prognostic function of Ki67 for pathological complete response rate of neoadjuvant chemotherapy in triplenegative breast cancer［J］. Tumori, 2014, 100(2): 136-142. DOI: 10.1700/1491.16395. ［6］ Mantovani A. Cancer: inflaming metastasis［J］. Nature, 2009, 457(7225): 36-37. DOI: 10.1038/457036b. ［7］ Haddad CR, Guo L, Clarke S, et al. Neutrophiltolymphocyte ratio in head and neck cancer［J］. J Med Imaging Radiat Oncol, 2015, 59(4): 514-519. DOI: 10.1111/17549485.12305. ［8］ Kang MH, Go SI, Song HN, et al. The prognostic impact of the neutrophiltolymphocyte ratio in patients with smallcell lung cancer［J］. Br J Cancer, 2014, 111(3): 452460. DOI: 10.1038/bjc.2014.317. ［9］ Feng JF, Huang Y, Liu JS. Combination of neutrophil lymphocyte ratio and platelet lymphocyte ratio is a useful predictor of postoperative survival in patients with esophageal squamous cell carcinoma［J］. Onco Targets Ther, 2013, 6: 16051612. DOI: 10.2147/OTT.S52501. ［10］ Xue P, Kanai M, Mori Y, et al. Neutrophiltolymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients［J］. Cancer Med, 2014, 3(2): 406-415. DOI: 10.1002/cam4.204. ［11］ Rachidi S, Wallace K, Wrangle JM, et al. Neutrophiltolymphocyte ratio and overall survival in all sites of head and neck squamous cell carcinoma［J］. Head Neck, 2016, 38 Suppl 1: E1068-E1074. DOI: 10.1002/hed.24159. ［12］ Adams S, Gray RJ, Demaria S, et al. Prognostic value of tumorinfiltrating lymphocytes in triplenegative breast cancers from two phase Ⅲ randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199［J］. J Clin Oncol, 2014, 32(27): 2959-2966. DOI: 10.1200/JCO.2013.55.0491. ［13］ HernandezAya LF, ChavezMacgregor M, Lei X, et al. Nodal status and clinical outcomes in a large cohort of patients with triplenegative breast cancer［J］. J Clin Oncol, 2011, 29(19): 2628-2634. DOI: 10.1200/JCO.2010.32.1877. ［14］ Foulkes WD, Metcalfe K, Hanna W, et al. Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1related breast carcinoma［J］. Cancer, 2003, 98(8): 15691577. DOI: 10.1002/cncr.11688. ［15］ Aggarwal BB, Gehlot P. Inflammation and cancer: how friendly is the relationship for cancer patients?［J］. Curr Opin Pharmacol, 2009, 9(4): 351-369. DOI: 10.1016/j.coph.2009.06.020. ［16］ Curry JM, Sprandio J, Cognetti D, et al. Tumor microenvironment in head and neck squamous cell carcinoma［J］. Semin Oncol, 2014, 41(2): 217-234. DOI: 10.1053/j.seminoncol.2014.03.003.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[4]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[5]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[6]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[7]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[8]	Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222.
[9]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[10]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[11]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[12]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[13]	Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185.
[14]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[15]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.